{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:17:32Z","timestamp":1794889052326,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for relapsed\/refractory hematologic malignancies; however, data on patient-reported outcomes in CAR-T are limited. We conducted a longitudinal study of adults with hematologic malignancies receiving CAR-T. We assessed quality of life (QOL; functional assessment of cancer therapy\u2013general), psychological distress (hospital anxiety and depression scale, patient health questionnaire-9, posttraumatic stress disorder [PTSD] checklist), and physical symptoms (Edmonton symptom assessment scale\u2013revised) at baseline, 1\u00a0week, 1, 3, and 6\u00a0months after CAR-T. We used linear mixed models to identify factors associated with QOL trajectory. We enrolled 103 of 142 eligible patients (3 did not receive CAR-T). QOL (B\u00a0= 1.96; P\u00a0&amp;lt; .001) and depression (B\u00a0=\u00a0\u22120.32; P\u00a0= .001) worsened by 1\u00a0week and improved by 6\u00a0months after CAR-T. At 6\u00a0months, 18%, 22%, and 22% reported clinically significant depression, anxiety, and PTSD symptoms, respectively. At 1\u00a0week, 52% reported severe physical symptoms, declining to 28% at 6\u00a0months after CAR-T. In unadjusted linear mixed models, worse Eastern Cooperative Oncology Group performance status (B\u00a0= 1.24; P\u00a0= .042), receipt of tocilizumab (B\u00a0= 1.54; P\u00a0= .042), and receipt of corticosteroids for cytokine release syndrome and\/or neurotoxicity (B\u00a0= 2.05; P\u00a0= .006) were associated with higher QOL trajectory. After CAR-T, QOL declined, and depression increased early, followed by improvements in QOL, psychological distress, and physical symptoms by\u00a06\u00a0months after infusion. A significant minority of patients reported substantial psychological distress and physical symptoms longitudinally.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009117","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T09:02:25Z","timestamp":1680166945000},"page":"3541-3550","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-6608","authenticated-orcid":false,"given":"P. Connor","family":"Johnson","sequence":"first","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-2061","authenticated-orcid":false,"given":"Tejaswini","family":"Dhawale","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Newcomb","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-9644","authenticated-orcid":false,"given":"Hermioni L.","family":"Amonoo","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"3Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"4Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W.","family":"Lavoie","sequence":"additional","affiliation":[{"name":"5University of Massachusetts Chan Medical School, Worchester, MA"},{"name":"6Department of Psychiatry, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-5626","authenticated-orcid":false,"given":"Dagny","family":"Vaughn","sequence":"additional","affiliation":[{"name":"6Department of Psychiatry, Massachusetts General Hospital, Boston, MA"},{"name":"7University of Tennessee Health Science Center College of Medicine, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-2622","authenticated-orcid":false,"given":"Kyle","family":"Karpinski","sequence":"additional","affiliation":[{"name":"6Department of Psychiatry, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"issue":"16","key":"2023072114300392200_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023072114300392200_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023072114300392200_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023072114300392200_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"2023072114300392200_bib5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"2023072114300392200_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-CELL therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2023072114300392200_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2023072114300392200_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2023072114300392200_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023072114300392200_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.6004\/jnccn.2020.7678","article-title":"Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy","volume":"19","author":"Johnson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"11","key":"2023072114300392200_bib11","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1080\/10428194.2020.1786563","article-title":"Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas","volume":"61","author":"Johnson","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023072114300392200_bib12","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"issue":"12","key":"2023072114300392200_bib13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023072114300392200_bib14","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12\u00a0months after chimeric antigen receptor T\u00a0cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023072114300392200_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2023072114300392200_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023072114300392200_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2023072114300392200_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12888-020-02885-6","article-title":"The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital","volume":"20","author":"Sun","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"9","key":"2023072114300392200_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"2023072114300392200_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1023\/A:1024719104351","article-title":"Validation of the PTSD checklist-civilian version in survivors of bone marrow transplantation","volume":"12","author":"Smith","year":"1999","journal-title":"J\u00a0Trauma Stress"},{"issue":"3","key":"2023072114300392200_bib21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton symptom assessment system 25 years later: past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"15","key":"2023072114300392200_bib22","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/cncr.28699","article-title":"Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy","volume":"120","author":"Miaskowski","year":"2014","journal-title":"Cancer"},{"issue":"7","key":"2023072114300392200_bib23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.1988.00380070082020","article-title":"Clinical symptoms and length of survival in patients with terminal cancer","volume":"148","author":"Reuben","year":"1988","journal-title":"Arch Intern Med"},{"issue":"23","key":"2023072114300392200_bib24","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1002\/cncr.30912","article-title":"The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer","volume":"123","author":"Nipp","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"2023072114300392200_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023072114300392200_bib26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023072114300392200_bib27","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023072114300392200_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023072114300392200_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jclinepi.2005.07.008","article-title":"Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches","volume":"58","author":"Yost","year":"2005","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"2023072114300392200_bib30","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","year":"2001","journal-title":"Eur J Cancer"},{"issue":"18","key":"2023072114300392200_bib31","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/cncr.28758","article-title":"Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy","volume":"120","author":"Pearman","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"2023072114300392200_bib32","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2023072114300392200_bib33","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2023072114300392200_bib34","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.2016.16786","article-title":"Effect of inpatient palliative care on quality of life 2\u00a0weeks after hematopoietic stem cell transplantation: a randomized clinical trial","volume":"316","author":"El-Jawahri","year":"2016","journal-title":"JAMA"},{"issue":"32","key":"2023072114300392200_bib35","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1200\/JCO.2017.73.2800","article-title":"Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6\u00a0months after transplant: results of a randomized clinical trial","volume":"35","author":"El-Jawahri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023072114300392200_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12885-020-07773-6","article-title":"Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population","volume":"21","author":"Hammermuller","year":"2021","journal-title":"BMC Cancer"},{"issue":"26","key":"2023072114300392200_bib37","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2023072114300392200_bib38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3541\/2065221\/blooda_adv-2022-009117-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3541\/2065221\/blooda_adv-2022-009117-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T10:35:23Z","timestamp":1689935723000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3541\/495093\/Longitudinal-patient-reported-outcomes-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":38,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009117","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}